

## Corona News 02/04/2021 Corona vaccination summit

**104 million infections worldwide Germany reached 2,252,000 with 46,781 deaths**

**Infection rates: USA 26.5 million, India 10.8 million, Brazil 9.3 million, Russia 3.8 million EU: France 3.3 million, Spain 2.9 million, Italy 2.6 million England 3.9 million 2.3 million deaths worldwide. Turkey and Colombia over 2 million cases of infection. 21 countries over 1 million**

Numbers copyright: Johns Hopkins University & Medicine Coronavirus Resource Center

The great vaccination peak is over. It wasn't the big hit either. Here are the results announced by Ms. Merkel, Mr. Söder and Mr. Müller. At the beginning, Ms. Merkel once again explained the importance of the vaccinations and thanks the pharmaceutical companies for their commitment to production so far (there must have been a lot to Ms. Merkel). Then she tackles the problems at hand. Are the promised amounts that were once promised really coming? I can make a preliminary remark here: No, Ms. Merkel, if you had been attentive for the last 14 days, you would have known that Biontech and Moderna have promised quantity reductions and delivery problems for the EU, and AstraZeneca also sees problems and does not want to deliver completely. I'll say this in advance because I'm curious what the pharmaceutical industry will suddenly say at the vaccination summit. Fact status just now: All companies have currently announced reductions.

Continue with Ms. Merkel. The second question she asks, how does the comparison to other countries look like, you would hear "so this and that" from Israel, the USA and Great Britain. And the third point is what should be retained with the current approach in Germany and what should be changed. (Note: Nanana, Ms. Merkel, no national approach, always nicely coordinated with the EU. You know, nobody can defeat the pandemic on their own).

Then you really get started, you now have calculations of the deliveries for the individual quarters. A distinction must be made between approved and non-approved vaccines. In addition to the 3 known approved companies, 2 others also took part in the talks, namely Johnson & Johnson and CureVac. Both assume approvals in the second / third quarter. Both companies would already be pre-producing, for which they would have received money from the European Commission, i.e. also from the German taxpayer. (Note: As now, they produce a vaccine en masse, so to speak, although they don't even know that it may not be approved at all, and then throw it away or is the approval just a formality like with another pharmaceutical company?) . There is therefore a minimum variant and a maximum variant. The Ministry of Health has the figures.

There is still no vaccine available for around 9 million children, then it will come in the summer months at the earliest. We need a vaccine for around 73 million people. Even if the new approvals don't come, the vaccine is enough for everyone.

A comparison with other countries shows that the USA only produces in its own country for its own needs due to legislation, so that Europe is reduced to its own locations. (Note: If the USA only produces for itself, why do we actually also deliver from European locations to the USA?). Didn't answer you as a precaution. For good reasons, the European Commission did not opt for emergency approval, but for provisional approval, which is of a different quality. (Note: But not on the quality of the vaccine, it stays the same, right?). Israel deals with data very differently. The EU negotiated for a long time over liability issues and struggled for a long time. So there are good reasons that the EU's path was slower. (Note: That's right, you have now seen in the contract with AstraZeneca how holey it is in terms of delivery commitments. And so that citizens do not receive any information about details with the forced publication of the contract, and for the time being no officials, you have that large part of the contract blackened to cover up bad performance).

But Ms. Merkel has more to report. Now the exciting point what the federal government would like to keep. Attention: We are holding on to advertise the trust. WOW. The first hit of the day. But even then we can reassure Ms. Merkel. As responsible citizens, we already get an idea of the situation, reliability, etc. because nowadays there is the Internet. And we then compare the information from reputable sites with the statements of the federal politicians and determine where there are inconsistencies. Transparency when vaccinating is the top priority. (Note: I am delighted, Ms. Merkel, that you have finally brought back Mr Seibert's favorite sentence: The Federal Government provides information with facts and transparently. I suddenly get a feeling of choking in my throat.). Then she talks about the need for good management for the citizens when vaccination appointments can be made. A national vaccination strategy would now also contain a national vaccination plan, which should contain detailed information on when and where each vaccine arrives in order to improve the invitation management for citizens. And the great thing would be that for Biontech the delivery dates would be until 02/23/2021, for the others until 02/17/2021. (Note: WOW, a real foresight in the vaccination strategy, the first approaches from the new vaccination plan are already coming through).

Finally, Ms. Merkel comes to a special point, the federal government asked the pharmaceutical companies where they could support. And there are some points. Therefore, the Ministry of Economic Affairs will develop a platform where it will be made transparent, ampoules and stopper production, also the inoculation variants, syringes and the like, there must be looked, even with sensitive substances, how one can produce more. There are intermediate substances that are missing, otherwise more vaccine could be produced. But at the moment you don't have any manufacturers, the federal government wants to help with money and commitment, that also depends on the professional qualities.

At the end of the summer, at the end of the third quarter, there should be a vaccination offer for everyone.

Mr. Müller emphasizes again that 100,000 vaccine doses would be enough for 50,000 people and that it is therefore so important to know when the vaccine is available and in what quantity, and that as early as possible so that appropriate invitations can be issued. But you also got to know the complexity of the supply chains, deliveries, etc., the sensitive production chains and that you can't ramp it up overnight, that was certainly a learning process. (Note: Eat clearly, it is the first vaccine ever to be produced in the world. Who can know or even guess how difficult and complicated it can be). He was pleased that Bayer had agreed to work with CureVac and provide capacities, but that would take months, it would not be possible overnight. Fortunately, the situation in the vaccination centers is still relaxed. (Note: That's right, if there is nothing there, the rush of people entitled to vaccinate is small). The vaccine will remain scarce in the first quarter because production cannot be ramped up so quickly.

Mr. Söder is also pleased that such a meeting took place. Vaccination is the key to everything, so you shouldn't talk bad about the topic all the time, but you shouldn't talk nicely either. The EU has shown that everything has gone according to plan so far, the truth is that people see many differences in vaccination in Europe and other regions of the world. Precise planning of the availability of vaccines is not possible, only quarterly. You can't catch up with the others, but we have to improve. The pharmaceutical companies have made promises for the quarters but have not given any guarantees. He thinks that it was good that Ms. Merkel took the lead on this topic in order to bring in spiritual clarity. Mental clarity; Yes, Mr Söder, we often need them in German politics, but we look in vain.

When asked, Ms. Merkel brought the family doctors into play. Especially when there is a lot of vaccine available, the vaccination centers will be overwhelmed, especially if the vaccines do not have to be specially stored, the family doctor's practices can help. Companies like BASF have also said that they can vaccinate their employees themselves. But Mr. Söder sees the phase of family doctor participation still in the future. Since it is not yet clear whether vaccinated people can pass the virus on, there will be no additional freedom for vaccinated people at the moment. When asked why there were problems with distribution and why the EU was so stingy with money and possibly triggered the problems of the lower vaccine availability as a result, Ms. Merkel explained, the Biontech boss explained that more money would not have produced more vaccine. Of course, that's only half the story. As a precaution, she is hiding the fact that more money would of course have changed the distribution mechanism of the available vaccine worldwide and that the EU / Germany would have received more at the beginning. Furthermore, Ms. Merkel speaks of complicated approval processes for each individual component of the vaccine; if one is adjusted, it must be re-certified. Oops, what does Ms. Merkel say by the way: It may be that we have to vaccinate for many years, when the new mutation of the virus has to be inoculated again every year. Well then, happy vaccination.